Seeing criticism of $Recursion Pharmaceuticals (RXRX.US)$ ad...
Seeing criticism of $Recursion Pharmaceuticals(RXRX.US$ adding +$1 bil in Mcap on a $50 mil investment from $NVIDIA(NVDA.US$ ,that's fine if you only look at today's news...
But this is a huge endorsement from top AI hardware/service provider that launched a drug discovery cloud service business this yr
But this is a huge endorsement from top AI hardware/service provider that launched a drug discovery cloud service business this yr
$RXRX is the clear leader in AI-driven drug discovery w/ integrated wet-lab validation. The $NVDA partnership will accelerate dev of one of the largest biomolecular generative AI models
$RXRX is executing on all fronts:
14 to 23 petabytes of bio/chem data over the last yr, plus multiple tech acquisitions
Internal Pipeline: 4 clinical trials (3 Ph2)
Drug disc. partners with $BAYER AG(BAYRY.US$ & $ROCHE HOLDING AG(RHHBY.US$ that incl. $230 mil upfront + $14 bil in milestones + royalties
14 to 23 petabytes of bio/chem data over the last yr, plus multiple tech acquisitions
Internal Pipeline: 4 clinical trials (3 Ph2)
Drug disc. partners with $BAYER AG(BAYRY.US$ & $ROCHE HOLDING AG(RHHBY.US$ that incl. $230 mil upfront + $14 bil in milestones + royalties
$RXRX had $473 mil cash at end of Mar + $50 mil investment from $NVDA= 2+ yrs cash runway,
With potential for more partners or milestone pymts from $BAYRY & $RHHBY,
Yes, adding $1 bil in Mcap on a $50 mil investment is a lot, but $RXRX still looks cheap/great LT buy
With potential for more partners or milestone pymts from $BAYRY & $RHHBY,
Yes, adding $1 bil in Mcap on a $50 mil investment is a lot, but $RXRX still looks cheap/great LT buy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
